Drug intelligence / Profile preview

MI180021

Development stage: Preclinical
Lead developer: PharmaMar
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MI180021 is an investigational antibody-drug conjugate (ADC) developed by PharmaMar. It consists of the HER2-targeting monoclonal antibody trastuzumab conjugated to PM160057, a novel marine-derived cytotoxic payload. PM160057 belongs to a new family of DNA-binding molecules that induce cell death in tumor cells. MI180021 is designed to selectively target HER2-overexpressing cancers, including breast, gastric, and pancreatic cancers. Preclinical data presented at the 2018 World ADC Congress highlighted its potent and highly selective activity against these tumor types.

Targets

DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on MI180021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MI180021.

Explore the full profile